Psoriatic Arthritis

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

By

TNFi persistence and factors influencing persistence were investigated in patients who were treated with TNFi therapy for the first time.

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

By

Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

By

Administration of abatacept may improve patient-reported outcomes in individuals with active psoriatic arthritis and elevated levels of C-reactive protein, irrespective of tumor necrosis factor inhibitor treatment history.

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

By

The guideline includes recommendations for treating adult patients with active psoriatic arthritis.

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

By

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

By

The risk for symptom flares is substantial after TNFi discontinuation in patients with psoriatic arthritis who had achieved remission/low disease activity.

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

By

Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

By

With the exception of sedentary lifestyle, cardiovascular risk factors were not found to impact the likelihood of achieving minimal disease activity among patients with psoriatic arthritis.

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

By

Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.

Secukinumab Effectively Inhibits Radiographic Progression of PsA

Secukinumab Effectively Inhibits Radiographic Progression of PsA

By

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Tofacitinib Safety Comparable With Biologics

Tofacitinib Safety Comparable With Biologics

By

The real-world rates of most adverse events in patients with psoriatic arthritis receiving several biologics may be comparable with those reported in phase 3 studies of tofacitinib.

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

By

Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

By

Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.

Tofacitinib May Reduce Disease Activity in Active Psoriatic Arthritis

Tofacitinib May Reduce Disease Activity in Active Psoriatic Arthritis

By

Tofacitinib may be effective in reducing psoriatic arthritis activity in patients with inadequate response to TNF inhibitors.

Current Status of Targeting Remission in Patients With Psoriatic Arthritis

Current Status of Targeting Remission in Patients With Psoriatic Arthritis

By

Although remission is the ultimate goal among patients with psoriatic arthritis and their physicians, many unanswered questions on what precisely we should aim to achieve still remain.

FDA Approves Simponi Aria For Active Ankylosing Spondylitis, Psoriatic Arthritis

FDA Approves Simponi Aria For Active Ankylosing Spondylitis, Psoriatic Arthritis

By

Simponi Aria has been approved by the FDA for treating PsA or ankylosing spondylitis.

Safety and Efficacy of Intravenous Golimumab in Psoriatic Arthritis

Safety and Efficacy of Intravenous Golimumab in Psoriatic Arthritis

By

Psoriatic arthritis treatment with intravenous golimumab leads to improved outcomes.

Novel Interleukin Inhibitors Efficacious for Psoriatic Arthritis

Novel Interleukin Inhibitors Efficacious for Psoriatic Arthritis

By

Inhibitors of interkeukins 6, 12, 23 and 17A were shown to be effective and generally well-tolerated agents for the treatment of psoriatic arthritis.

Biomarkers of Peripheral and Axial Arthritis in Psoriatic Disease

Biomarkers of Peripheral and Axial Arthritis in Psoriatic Disease

By

Study confirms the validity of previously identified bone-turnover biomarkers for psoriatic disease-associated arthritis and for axial arthritis.

Psoriatic Arthritits Patients Maintain Clinical Improvement With Long-Term Secukinumab

Psoriatic Arthritits Patients Maintain Clinical Improvement With Long-Term Secukinumab

By

Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

By

Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

By

HBV reactivation rates were lower among all chronic HBV infection patients on antiviral prophylaxis, regardless of whether they were receiving TNF inhibitors.

Real-World Data Validates Minimal Disease Activity Index in PsA

Real-World Data Validates Minimal Disease Activity Index in PsA

By

Overall improvements in rates of minimal disease activity are achieved in patients with PsA when they are treated with anti-tumor necrosis factor agents

No Association Between Opioid Intake and Patient Satisfaction After Ankle Fracture

No Association Between Opioid Intake and Patient Satisfaction After Ankle Fracture

By

To improve pain relief, surgeons should proactively address stress, distress, and ineffective coping strategies.

Positive Correlation Between Smoking Amount, Duration and Psoriasis

Positive Correlation Between Smoking Amount, Duration and Psoriasis

By

Smoking is associated with the risk of psoriasis.

Sonographic Enthesitis as a Potential Marker of Radiographic Damage Severity in PsA

Sonographic Enthesitis as a Potential Marker of Radiographic Damage Severity in PsA

By

The association between sonographic enthesitis and severity of radiographic features of peripheral and axial joint damage in psoriatic arthritis was examined in a cross-sectional study.

Noninvasive Test Monitors Hepatic Fibrosis in Psoriasis Patients Taking Methotrexate

Noninvasive Test Monitors Hepatic Fibrosis in Psoriasis Patients Taking Methotrexate

By

A noninvasive test can be used to help monitor for risk of worsening fibrosis in psoriasis patients who have elevated hepatic steatosis.

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

By

The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk

FDA Approval of Biosimilar Cyltezo for Multiple Indications

FDA Approval of Biosimilar Cyltezo for Multiple Indications

By

Cyltezo subcutaneous injection has been approved by the FDA.

Findings of Psoriatic Arthritis Treatment Trends

Findings of Psoriatic Arthritis Treatment Trends

By

Less than 40% of psoriatic arthritis patients were treated with a bDMARD.

Sign Up for Free e-newsletters